THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, November 14, 2024
FREMONT, CA: Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that uses traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, eliminating the need for specialized solid-phase reactors. This innovative LPPS technology significantly minimizes solvent demand and the need for additional reagents when compared to traditional solid-state peptide synthesis processes.
"Over the past several years, we have made significant investments in the research and development of complex synthetics, specifically to reduce the economic and environmental impacts of manufacturing peptides and oligonucleotides," said Dr. Matt Bio, Chief Scientific Officer, Cambrex. "Our new LPPS technology provides a significantly more cost-efficient and environmentally sustainable solution when compared to traditional solid-phase peptide synthesis, substantially reducing solvent usage and allowing the substitution of sustainable solvents."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The LPPS technology is capable of handling peptides up to 12 residues long, and longer peptides are then formed in liquid phase utilizing a convergent fragment coupling approach. Cambrex's LPPS technology enables processes to be scaled in the same way that traditional small molecules are.
In addition to the LPPS, Cambrex developed novel peptide and protein crystallization capabilities, including a crystallization screening platform designed exclusively to discover crystalline peptides and proteins. Crystallization can increase product quality and stability while minimizing the need for time-consuming preparative chromatography and lyophilization.
"With the clinical and commercial successes of peptide-based therapies, it's imperative that we provide industry-leading solutions to develop and scale peptide candidates," said Thomas Loewald, CEO at Cambrex.
Cambrex will continue to invest in R&D across complex synthetic modalities, including peptide technology development and new research into using artificial intelligence to optimize oligonucleotide operations.
More in News